Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$166.33
-0.1%
$157.26
$116.88
▼
$176.58
$206.43B0.356.36 million shs7.55 million shs
7 Stocks That Could Be Bigger Than Tesla, NVIDIA, and Google Cover

Could the next Tesla, NVIDIA, and Google be hiding in plain sight? Discover seven growth stocks with the potential to become tomorrow's market giants, fueled by breakthroughs in AI, nuclear energy, cybersecurity, and more.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
-0.12%-1.04%+8.31%+13.83%+29.87%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$166.33
-0.1%
$157.26
$116.88
▼
$176.58
$206.43B0.356.36 million shs7.55 million shs
7 Stocks That Could Be Bigger Than Tesla, NVIDIA, and Google Cover

Could the next Tesla, NVIDIA, and Google be hiding in plain sight? Discover seven growth stocks with the potential to become tomorrow's market giants, fueled by breakthroughs in AI, nuclear energy, cybersecurity, and more.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
-0.12%-1.04%+8.31%+13.83%+29.87%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
2.79
Moderate Buy$171.633.19% Upside

Current Analyst Ratings Breakdown

Latest GILD Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/18/2026
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
Set Price Target$175.00
11/16/2026
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
Boost Price TargetEqual Weight$145.00 ➝ $160.00
11/12/2026
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
Set Price Target$190.00
11/4/2026
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
Set Price Target$196.00
11/2/2026
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
Reiterated RatingOutperform$175.00
10/30/2026
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
Boost Price TargetBuy$175.00 ➝ $195.00
10/30/2026
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
Set Price Target$175.00
10/30/2026
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
Boost Price TargetBuy$160.00 ➝ $175.00
10/30/2026
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
Reiterated RatingOutperform$184.00
10/30/2026
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
Boost Price TargetOverweight$170.00 ➝ $190.00
(Data available from 11/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$29.44B7.01$10.46 per share15.90$10.44 per share15.93
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$8.51B-$3.16N/A16.44N/A-12.47%-1.85%-0.61%2/9/2027 (Estimated)

Latest GILD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
10/29/2026Q3 2026
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$2.19$2.55+$0.36$1.94$7.81 billion$8.30 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$3.281.97%+3.04%N/A 10 Years

Latest GILD Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
10/27/2026
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
quarterly$0.821.98%12/15/202612/15/202612/30/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
1.84
1.38
1.22

Institutional Ownership

CompanyInstitutional Ownership
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
83.67%

Insider Ownership

CompanyInsider Ownership
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
0.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
17,0001.24 billion1.24 billionOptionable

Recent News About These Companies

Best Medical Stocks To Consider - November 21st
Medical Stocks To Follow Today - November 20th
Gilead Sciences (NASDAQ:GILD) Insider Sells $4,775,400.00 in Stock
Where Could Gilead's Next Growth Come From?
Gilead Sciences, Inc. $GILD Shares Purchased by Boston Partners

New MarketBeat Followers Over Time

Media Sentiment Over Time

Gilead Sciences stock logo

Gilead Sciences NASDAQ:GILD

$166.33 -0.20 (-0.12%)
Closing price 11/20/2026 03:59 PM Eastern
Extended Trading
$167.22 +0.89 (+0.53%)
As of 11/20/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.